Brittle bone kids: is romosozumab safe Long-Term?
NCT ID NCT07366086
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study follows children and teens with osteogenesis imperfecta (brittle bone disease) who previously received romosozumab in an earlier trial. Researchers will monitor 71 participants for side effects over time. The goal is to see if the drug is safe for long-term use in this young population.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
romosozumab
What this could lead to
If successful, this could confirm that romosozumab is safe for long-term use in children with brittle bone disease, potentially leading to a new treatment option.
What could go wrong
This is a follow-up safety study, not a test of effectiveness. It is small (71 participants) and only includes those who already tolerated the drug, so results may not apply to all patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOGENESIS IMPERFECTA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Indiana University
RECRUITINGIndianapolis, Indiana, 46202, United States
-
Okayama Saiseikai Outpatient Center Hospital
RECRUITINGOkayama, Okayama-ken, 700-0013, Japan
-
Universitaetsklinikum Koeln
RECRUITINGCologne, 50937, Germany
-
Universitaetsklinikum Wuerzburg
RECRUITINGWürzburg, 97074, Germany